DMAA
Drugs Made In America Acquisition Corp. Rights
NASDAQ: DMAAR · ·
$0.12
+0.00% today
Updated 2026-10-16
Market cap
$1.83M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$—
Dividend yield
—
52W range
$0 – $0
Volume
0.0M
WallStSmart proprietary scores
15
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D5.0
Quality
C+3.5
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →275 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | TTM |
|---|---|
| Revenue | — |
| Net income | — |
| EPS | $— |
| Free cash flow | — |
| Profit margin | — |
Peer comparison
| Company | Mkt Cap | Score | Growth | Profit | Value | Quality | MoS | Rating |
|---|---|---|---|---|---|---|---|---|
| DMAAR | $1.83M | 15 | 3.7 | 3.5 | 5.0 | 5.0 | — | Avoid |
Smart narrative
Drugs Made In America Acquisition Corp. Rights trades at $0.12. Our Smart Value Score of 15/100 indicates the stock is weak.
Frequently asked questions
What is Drugs Made In America Acquisition Corp. Rights's stock price?
Drugs Made In America Acquisition Corp. Rights (DMAAR) trades at $0.12.
Is Drugs Made In America Acquisition Corp. Rights overvalued?
Drugs Made In America Acquisition Corp. Rights carries a Smart Value Score of 15/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
Company info
Sector—
Industry—
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE—
Beta—
50D MA$0.00
200D MA$0.00
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—